ConductScience.org, home

Paper38899693

Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.

Melani C and 35 others. N Engl J Med, 2024. Cited by 71 papers, by iCite.

Cite this record

ConductScience Library. Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma. Papers, record 38899693. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38899693

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.
PubMed
Journal
N Engl J Med
PubMed
Year
2024
PubMed
Publication types
Journal Article, Clinical Trial, Phase I, Clinical Trial, Phase II, Research Support, N.I.H., Intramural
PubMed
Citations, by iCite
71
iCite
Relative citation ratio, by iCite
8.18, provisional
iCite
Revised in PubMed
2025-05-30
PubMed

Authors36

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Melani CChristopherhttps://orcid.org/0000-0002-9661-4570
2Lakhotia RRahul
3Pittaluga SStefania
4Phelan JDJames D
5Huang DWDa Wei
6Wright GGeorge
7Simard JJillian
8Muppidi JJagan
9Thomas CJCraig J
10Ceribelli MMichele
11Tosto FAFrances A
12Yang YYandan
13Xu WWeihong
14Davies-Hill TTheresa
15Pack SDSvetlana D
16Peer CJCody J
17Arisa OOluwatobi
18Mena EEsther
19Lindenberg LLiza
20Bergvall EEthan

Source PubMed

See all 36 authorsDownload CSV of authors

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, Monoclonal, HumanizedMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
LenalidomideMajor topic
Lymphoma, Large B-Cell, DiffuseMajor topic
PiperidinesMajor topic
Adult
Aged
Aged, 80 and over
Female
Humans
Male
Middle Aged
Adenine
Bridged Bicyclo Compounds, Heterocyclic
Molecular Targeted Therapy
Prednisone
Progression-Free Survival
Pyrazoles
Pyrimidines
Recurrence
Sulfonamides

Source PubMed

Download CSV of topics

Grants8

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
Z99 CA999999Intramural NIH HHSUnited StatesZ99CA999999PubMedNIH RePORTER
ZIABC011006NIHNIH RePORTER
ZIABC011772NIHNIH RePORTER
ZIABC011780NIHNIH RePORTER
ZIASC000550NIHNIH RePORTER
ZIATR000047NIHNIH RePORTER
ZICSC006536NIHNIH RePORTER
ZICSC006537NIHNIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03223610Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References40

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135653592The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.Blood2022https://conductscience.org/library/papers/35653592PubMed
232289277A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.Cancer Cell2020https://conductscience.org/library/papers/32289277PubMed
322885699Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.Nature2012https://conductscience.org/library/papers/22885699PubMed
428095146Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.J Clin Oncol2017https://conductscience.org/library/papers/28095146PubMed
531331917Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.Blood2019https://conductscience.org/library/papers/31331917PubMed
635717989
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Lancet2022https://conductscience.org/library/papers/35717989PubMed
725842160Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study.Lancet Oncol2015https://conductscience.org/library/papers/25842160PubMed
834516954Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.Lancet Oncol2021https://conductscience.org/library/papers/34516954PubMed
929713087Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.Nat Med2018https://conductscience.org/library/papers/29713087PubMed
1028774879Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.Blood2017https://conductscience.org/library/papers/28774879PubMed
1121495023Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.Cancer2011https://conductscience.org/library/papers/21495023PubMed
1226639348Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.N Engl J Med2016https://conductscience.org/library/papers/26639348PubMed
1338701792Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas.Cancer Cell2024https://conductscience.org/library/papers/38701792PubMed
1410676951Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.Nature2000https://conductscience.org/library/papers/10676951PubMed
1523045577Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.J Clin Oncol2013https://conductscience.org/library/papers/23045577PubMed
161406976Cooperative interaction between c-myc and bcl-2 proto-oncogenes.Nature1992https://conductscience.org/library/papers/1406976PubMed
1728552327Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.Cancer Cell2017https://conductscience.org/library/papers/28552327PubMed
1829925955A multiprotein supercomplex controlling oncogenic signalling in lymphoma.Nature2018https://conductscience.org/library/papers/29925955PubMed
1922698399Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.Cancer Cell2012https://conductscience.org/library/papers/22698399PubMed
2029641966Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.N Engl J Med2018https://conductscience.org/library/papers/29641966PubMed

See all 40 referencesDownload CSV of references

Cited by46

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 71 citations.

PMIDTitleJournalYearIn PapersSource
42972012The cyclin-G associated kinase (GAK) is a clinically actionable drug target required for mitosis in diffuse large B-cell lymphoma.Leukemia2026https://conductscience.org/library/papers/42972012PubMed
42851176[Clinical characteristics of acute thrombocytopenia in newly diagnosed follicular lymphoma patients receiving obinutuzumab chemotherapy].Zhonghua Xue Ye Xue Za Zhi2026https://conductscience.org/library/papers/42851176PubMed
42558624Targeting NOP14 remodels the tumor immune microenvironment and enhances the antitumor efficacy of PD-1 blockade in DLBCL.Front Immunol2026https://conductscience.org/library/papers/42558624PubMed
42533058Patient cell drug profiling identifies p53-linked vulnerabilities in refractory lymphoid malignancies.NPJ Precis Oncol2026https://conductscience.org/library/papers/42533058PubMed
42513315A Multi-Targeted Strategy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: Real-World Outcomes of the ViPOR Regimen.J Clin Med2026https://conductscience.org/library/papers/42513315PubMed
42487683Molecular Pathogenesis and Therapeutic Response of Diffuse Large B Cell Lymphoma Genetic Subtypes.Annu Rev Cancer Biol2026https://conductscience.org/library/papers/42487683PubMed
42439665Diffuse Large B-Cell Lymphoma: From Molecular Stratification to Precision Immunotherapy.Cells2026https://conductscience.org/library/papers/42439665PubMed
42409736[Construction of a methionine metabolism-related prognostic signature and the effect of targeting methionine metabolism on diffuse large B-cell lymphoma].Zhonghua Xue Ye Xue Za Zhi2026https://conductscience.org/library/papers/42409736PubMed
42284698Analysis of cell-free DNA in lymphomas: from sample collection to genotyping and minimal residual disease monitoring.Blood Adv2026https://conductscience.org/library/papers/42284698PubMed
42278551Molecular Insights and Novel Therapies for Lymphoproliferative Disorders.Int J Mol Sci2026https://conductscience.org/library/papers/42278551PubMed
42099680Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.Hemasphere2026https://conductscience.org/library/papers/42099680PubMed
41824782Phase 1 study of zanubrutinib plus lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.Blood Adv2026https://conductscience.org/library/papers/41824782PubMed
41749954Lipid Metabolism Reprogramming in Diffuse Large B-Cell Lymphoma (DLBCL): Mechanisms and Treatment Strategies.Cancers (Basel)2026https://conductscience.org/library/papers/41749954PubMed
41684587Bcl-2 inhibitor resistance in diffuse large b-cell lymphoma: establishing a prognostic signature and targeting alpha protein kinase 1.Front Oncol2026https://conductscience.org/library/papers/41684587PubMed
41657780Novel therapeutic strategies targeting resistance mechanisms in hematologic malignancies: from BCL2 inhibition to immunomodulatory approaches.Front Pharmacol2025https://conductscience.org/library/papers/41657780PubMed
416543182026 Update on the Management of Diffuse Large B-Cell Lymphoma.Am J Hematol2026https://conductscience.org/library/papers/41654318PubMed
41591906RHOA controls oncogenic B cell receptor signaling in aggressive lymphoma.Proc Natl Acad Sci U S A2026https://conductscience.org/library/papers/41591906PubMed
41556969Mutational profiling of HIV+ diffuse large B-cell lymphoma reveals distinct mutational features with evidence of genomic instability.AIDS2026https://conductscience.org/library/papers/41556969PubMed
41348035Molecular subtypes of DLBCL: are we ready to translate our knowledge into the change of treatment paradigms?Hematology Am Soc Hematol Educ Program2025https://conductscience.org/library/papers/41348035PubMed
41310404The prognostic and clinical utility of circulating tumor DNA in diffuse large B-cell lymphoma: a systematic review and meta-analysis.NPJ Precis Oncol2025https://conductscience.org/library/papers/41310404PubMed

See all 46 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BCL2596PubTator's text mininghttps://conductscience.org/library/genes/596NCBI Gene
BCL6604PubTator's text mininghttps://conductscience.org/library/genes/604NCBI Gene
MYC4609PubTator's text mininghttps://conductscience.org/library/genes/4609NCBI Gene

Download CSV of genes

Drugs5

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
OBINUTUZUMABCHEMBL1743048Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1743048ChEMBL
IBRUTINIBCHEMBL1873475Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1873475ChEMBL
VENETOCLAXCHEMBL3137309Derived from the trial1https://conductscience.org/library/drugs/CHEMBL3137309ChEMBL
PREDNISONECHEMBL635Derived from the trial1https://conductscience.org/library/drugs/CHEMBL635ChEMBL
LENALIDOMIDECHEMBL848Derived from the trial1https://conductscience.org/library/drugs/CHEMBL848ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38899693

GET https://conductscience.org/api/papers/v1/38899693/authors?page=2